Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Branaplam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 2,490Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Safety worries spur Novartis to suspend drug dosing in Huntington’s trial
    Safety worries spur Novartis to suspend drug dosing in Huntington’s trial

    25 Aug 2022

    // Jonathan Gardner BIOPHARMADIVE

    https://www.biopharmadive.com/news/novartis-branaplam-huntingtons-disease-safety-suspend-dosing/630423/

    Jonathan Gardner BIOPHARMADIVE
    25 Aug 2022
    Share Share
    Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
    Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam

    08 Aug 2022

    // Dr. Leora Fox HDBUZZ

    https://en.hdbuzz.net/328

    Dr. Leora Fox HDBUZZ
    08 Aug 2022
    Share Share
    Novartis receives USFDA Orphan Drug Designation for branaplam (LMI070)
    Novartis receives USFDA Orphan Drug Designation for branaplam (LMI070)

    20 Oct 2020

    // PRESS RELEASE

    https://www.novartis.com/news/media-releases/novartis-receives-us-food-and-drug-administration-fda-orphan-drug-designation-branaplam-lmi070-huntington%27s-disease-hd

    PRESS RELEASE
    20 Oct 2020
    Share Share
    Novartis to pursue SMA drug branaplam in Huntington's disease
    Novartis to pursue SMA drug branaplam in Huntington's disease

    20 Oct 2020

    // REUTERS

    https://www.reuters.com/article/us-novartis-branaplam-huntingtons-s-dise/novartis-to-pursue-sma-drug-branaplam-in-huntingtons-disease-idUSKBN2760KN

    REUTERS
    20 Oct 2020
    Share Share
    Novartis R&D boss says doesn't see big opportunity in oral SMA therapy
    Novartis R&D boss says doesn't see big opportunity in oral SMA therapy

    05 Dec 2019

    // John Miller REUTERS

    https://www.reuters.com/article/us-novartis-investors-sma/novartis-rd-boss-says-doesnt-see-big-opportunity-in-oral-sma-therapy-idUSKBN1Y91S0

    John Miller REUTERS
    05 Dec 2019
    Share Share
    Genentech takes aim at Biogen and Novartis, highlighting an early +ve results
    Genentech takes aim at Biogen and Novartis, highlighting an early +ve results

    03 Oct 2018

    // John Carroll ENDPTS

    https://endpts.com/genentech-takes-aim-at-biogen-and-novartis-highlighting-an-early-look-at-positive-results-for-their-oral-sma-drug-from-ptc/

    John Carroll ENDPTS
    03 Oct 2018
    Share Share